iBio's IBIO-610 Shows Fat-Selective Weight Loss in Non-Human Primate Study
核心洞察
iBio's IBIO-610 (搜索), a first-in-class Activin E (搜索) antibody, reduced visceral fat by 6.7% and total fat mass by 5.2% in obese non-human primates despite high-calorie diet.
The treatment demonstrated fat-selective weight loss while maintaining lean mass, with an extended 33.2-day half-life supporting potential twice-yearly dosing.
Results align with previous rodent studies and human clinical trials targeting the Activin E (搜索) pathway, supporting continued development for obesity (搜索) and cardiometabolic diseases (搜索).
iBio, Inc. announced new preclinical data demonstrating that IBIO-610 (搜索), a potentially first-in-class Activin E (搜索) antibody candidate, achieved fat-selective weight loss in obese non-human primates (NHPs). The study showed a 6.7% reduction in visceral fat and 5.2% reduction in total fat mass following two once-every-eight-week doses, despite animals being maintained on a high-calorie diet.
The preclinical body composition data represents a significant milestone for the AI-driven biotech company's obesity (搜索) and cardiometabolic disease program. IBIO-610 (搜索) reduced fat mass in obese NHPs compared to vehicle-treated controls in what the company characterized as a small, not statistically powered study. Notably, the treatment produced only a slight increase in lean mass, demonstrating the fat-selective profile that distinguishes this approach from conventional weight loss therapies.
Extended Half-Life Supports Convenient Dosing
Previously reported pharmacokinetic data from the same study revealed IBIO-610 (搜索)'s extended 33.2-day half-life in obese NHPs, with projections suggesting a human half-life of up to 100 days. This extended duration supports the potential for convenient twice-yearly dosing, which could represent a significant advantage over current obesity (搜索) treatments requiring more frequent administration.
"These data reinforce IBIO-610 (搜索)'s potential to deliver fat-selective improvements in body composition while maintaining lean mass," said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. "When added to the previously demonstrated extended half-life, these results further confirm the potential of IBIO-610 as a first-in-class therapy, and the capability of our AI-enabled discovery platform to address complex targets obesity (搜索), cardiometabolic and cardiopulmonary diseases (搜索), and may significantly improve the lives of patients."
Consistent with Activin E Pathway Effects
The fat-selective profile observed in the NHP study aligns with effects previously demonstrated in rodent models and with body composition outcomes reported by other companies in human clinical trials targeting the Activin E (搜索) pathway. This consistency across species and platforms strengthens the scientific rationale for IBIO-610 (搜索)'s continued development.
"These findings are consistent with body composition effects reported for therapies targeting the Activin E (搜索) pathway, including human siRNA approaches," said Cory Schwartz, Ph.D., Director of Research and Early Development at iBio. "We believe IBIO-610 (搜索)'s fat-selective biology supports its potential to drive targeted fat loss while maintaining lean mass. Our team is continuing its thorough analyses of the dataset spanning metabolic, biomarker, and mechanistic endpoints, and we look forward to presenting additional insights."
Comprehensive Dataset Analysis Ongoing
iBio plans to present the complete dataset, which will include analysis of additional biomarkers, at scientific conferences throughout 2026. The ongoing analysis encompasses metabolic, biomarker, and mechanistic endpoints that could provide deeper insights into IBIO-610 (搜索)'s mechanism of action and therapeutic potential.
The company positions IBIO-610 (搜索) as a differentiated therapy for obesity (搜索), cardiometabolic and cardiopulmonary diseases (搜索), leveraging its AI-enabled discovery platform to address complex therapeutic targets. iBio combines proprietary 3D modeling with innovative drug discovery platforms to develop what it describes as breakthrough antibody treatments for significant unmet medical needs.